Search

Your search keyword '"Meca-Lallana, Virginia"' showing total 207 results
Start Over Author "Meca-Lallana, Virginia" Publication Year Range Last 10 years
207 results on '"Meca-Lallana, Virginia"'

1. Real-World Experience with Diroximel Fumarate in Patients with Multiple Sclerosis: A Prospective Multicenter Study

Author

Aguirre, Clara, Alonso-Torres, Ana, Agüera, Eduardo, García-Domínguez, José Manuel, Montero-Escribano, Paloma, González-Quintanilla, Vicente, Costa-Frossard, Lucienne, Oreja-Guevara, Celia, Reyes-Garrido, Virginia, Caminero-Rodríguez, Ana Belén, Riancho, Javier, Sánchez, Octavio, Forero, Lucía, Pérez-Parra, Fernando, Ares-Luque, Adrián, Téllez, Nieves, Arzalluz-Luque, Joaquín, Iglesias, Federico, Casado-Ruiz, Virginia, Castellano-Vicente, Alberto José, Borrega, Laura, Galán, Victoria, de Antonio, Luis A. Rodríguez, Romero, Carlos, García-Rodríguez, Raquel, Cano-Orgaz, Antonio Tomás, Sánchez-Menoyo, José Luis, Pérez-Ruiz, Domingo, Gutiérrez-Martin, Fuencisla, Hernández-Echevarría, Luis, and Meca-Lallana, Virginia

Published
2024
Full Text
View/download PDF

2. Real-World Retrospective Analysis of Alemtuzumab Outcomes in Relapsing-Remitting Multiple Sclerosis: The LEMCAM Study

Author

Costa-Frossard França, Lucienne, Meca Lallana, Virginia, Labiano-Fontcuberta, Andrés, Blasco, Rosario, Monreal, Enric, Martínez Ginés, María Luisa, Aguirre, Clara, Sabin Muñoz, Julia, Sainz de la Maza, Susana, Cuello, Juan Pablo, Díaz-Pérez, Carolina, Chico García, Juan Luis, Lozano Ros, Alberto, Rodríguez Jorge, Fernando, Martínez Martínez, Susana, and García Domínguez, José Manuel

Published
2024
Full Text
View/download PDF

4. Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials

Author

Carra, Adriana Josefa, Deri, Norma Haydee, Jose, Jorge Gustavo, del Valle Liwacki, Susana, Mainella, Carolina Natalia, Pagani, Fatima, Povedano, Guillermo, Alfici, Alberto Rodriguez, Tavolini, Dario Raul, Buonanotte, Carlos Federico, Burgos, Marcos, Giugni, Juan Carlos, Artesi, Juan Jose Martin, Rojas, Juan Ignacio, Zuin, Daniel Raul, Videla, Hugo Osvaldo, Correale, Jorge Daniel, Luetic, Geraldine G., Hodgkinson, Suzanne, Lechner-Scott, Jeannette, Parratt, John, Saines, Noel, Reddel, Stephen, Wijeratne, Tissa, Taylor, Bruce, Deisenhammer, Florian, Traxler, Gerhard, Leutmezer, Fritz, Wipfler, Peter, Weber, Joerg R., Lampl, Christian, Bartholome, Emmanuel, Dive, Dominique, Glibert, Nele, Perrotta, Gaetano, Pesch, Vincent, Buyle, Maarten, Wijmeersch, Bart, Willekens, Barbara, Basagic, Edin, Mehmedika Suljic, Enra, Klupka-Sarić, Inge, Danovska, Maya, Dimitrova, Maria, Genov, Krasimir, Izmaylov, Alim, Mavrov, Radoslav, Milanov, Ivan, Naydenov, Valcho, Shotekov, Penko, Tarnev, Ivaylo, Traykov, Latchezar, Emond, Francois, Selchen, Daniel, Rivest, Donald, Sabella, Lisa, Witkowski, Ludivine, Saveriano, Alexander, Bolano Solano, Addinson Rene, Ruiz, Cesar Augusto Franco, Nassar Tobon, Andrea Catalina, Cardozo, Carlos Alberto Navas, Schlesenger, Antonio, Triana, Javier Dario, Sarabia, Osvaldo Elias Lara, Montero, Luis Alfonso Zarco, Arango, Jorge Andres Jimenez, Basic, Silvio, Pasic, Marija Bosnjak, Soldo, Silva Butkovic, Habek, Mario, Kidjemet-Piskac, Spomenka, Matijaca, Meri, Vuletic, Vladimira, Ampapa, Radek, Dufek, Michal, Grunermelova, Marketa, Mares, Jan, Martinkova, Alena, Peterka, Marek, Stetkarova, Ivana, Stourac, Pavel, Talab, Radomir, Tyblova, Michaela, Marta, Vachova, Valis, Martin, Hradilek, Pavel, Rockova, Petra, Gross-Paju, Katrin, Haldre, Sulev, Airas, Laura, Karppa, Mikko, Bourre, Bertrand, Casez, Olivier, Ciron, Jonathan, Kwitakowski, Arnaud, Labauge, Pierre, Lebrun Frenay, Christine, Michel, Laure, Derache, Nathalie, Vukusic, Sandra, Laplaud, David-Axel, Beridze, Maia, Chakhava, George, Gauarashvili, Ann, Giorgadze, Gvantsa, Guldedava, Nana, Janelidze, Marina, Kiziria, Marina, Shakarishvili, Roman, Tsiskaridze, Alexander, Chkhikvishvili, Shalva, Albert, Christian, Berthele, Achim, Yalachkov, Yavor, Pitarokoili, Kalliopi, Kallmann, Boris-Alexander, Klotz, Luisa, Oschmann, Patrick, Pul, Refik, Rau, Daniela, Skripuletz, Thomas, Chan, Koon Ho, Lau, Alexander Yuk Lun, Li, Jessica Tsz Ching, Wong, Wa Tai, Maria, Biro Zita, Bokor, Magdolna, Dobos, Eniko, Janszky, Jozsef, Kovacs, Krisztina, Lazarcsik, Ildiko, Piros, Palma, Rozsa, Csilla, Satori, Maria, Simo, Magdolna, Nagy, Ferenc, Behari, Madhuri, Kulkarni, Rahul, Kumar, Radhakrishanan Suresh, Dwivedee, Shamsher, Iype, Thomas, Baviskar, Rahul, Mathukumalli, Neeharika L., Gilad, Ronit, Karussis, Dimitrios, Milo, Ron, Shahien, Radi, Vaknin, Adi, Weller, Boaz, Wilf-Yarkoni, Adi, Achiron, Anat, Aguglia, Umberto, Di Gregorio, Maria, Calabrese, Massimiliano, Cordioli, Cinzia, Sessa, Edoardo, Tomassini, Valentina, Inglese, Matilde, Castro Farfan, Freddy Guillermo, Roldan, Giovana Femat, Gonzalez Guardado, Antonio, Lopez Meza, Elmer, Maldonado, Jair Fernando, Boschetti, Laura Ordonez, Partida Medina, Luis Roberto, Frequin, Stephan, Hupperts, Raymond, Schrijver, Hans, Smolders, Joost, Diaz, Cesar Abel Castaneda, Pretell, Edwin, Boczarska-Jedynak, Magdalena, Bonek, Robert, Brola, Waldemar, Darda-Ledzion, Lidia, Fryze, Waldemar, Maciejowski, Maciej, Rejdak, Konrad, Rosciszewska-Zukowska, Iwona, Selmaj, Krzysztof, Szymanska, Malgorzata, Zajda, Małgorzata, Zielinski, Tomasz, Beata, Zakrzewska-Pniewska, Adam, Stepien, Swiat, Maciej, Kim, Byoung Joon, Kim, Ho-Jin, Kim, Kwang-Kuk, Shin, Ha Young, Kim, Sung Min, Kim, Woojun, Oh, Jeeyoung, Bakhtiyarova, Klara Z., Belova, Anna N., Davydovskaya, Maria V., Dudin, Viacheslav A., Erina, Olesya V., Evdoshenko, Evgeny P., Greshnova, Irina V., Khabirov, Farit A., Kotov, Sergey V., Makarov, Nikolay S., Maslova, Natalia, Mishin, Gennadiy N., Pokhabov, Dmitry V., Smagina, Inna V., Spirin, Nikolay N., Trushnikova, Tatiana N., Volkova, Larisa I., Zaslavskiy, Leonid G., Zhukova, Natalia G., Ceranic, Mirjana, Cvijanovic, Vera, Drulovic, Jelena, Gavric Kezic, Mira, Jovanovic, Dragoslava, Milicevic, Svetlana K., Raicevic, Ranko, Suknjaja, Vesna, Boskovic Matic, Tatjana, Vojinovic, Slobodan, Ruiz, Luis Brieva, Castillo Trivino, Tamara, Costa-Frossard Franca, Lucienne, Eichau Madueno, Sara, Forero Diaz, Lucia, Martinez, Jose Enrique, Martinez Yelamos, Sergio, Meca Lallana, Virginia, Oreja Guevara, Celia, Ramio i Torrenta, Lluis, Arroyo Gonzalez, Rafael, Guo, Yuh-Cherng, Ro, Long-Sun, Tsai, Nai-Wen, Wang, Kai-Chen, Yang, Fu-Chi, Cherkez, Alla, Deineka, Natalia, Delva, Mykhaylo, Goloborodko, Alla, Hovbakh, Iryna, Khavunka, Marta, Kmyta, Oleksii, Kozyolkin, Olexandr, Lekomtseva, Yevgeniya, Litovchenko, Tetyana, Moskovko, Sergii, Pashkovskyy, Valeriy, Riabichenko, Tetiana, Tovazhnyanska, Olena, Voloshyna, Nataliya, Hrebeniuk, Hanna, Sokolova, Larysa, Arun, Tarunya, Constantinescu, Cris, Harrower, Timothy, Mattoscio, Miriam, Paling, David, Pearson, Owen, Robertson, Neil, Webb, Stewart, Cottrell, David, Nicholas, Richard, Duddy, Martin, Anadani, Nidhiben, Belkin, Martin, Bernitsas, Evanthia, Borazanci, Aimee, Clark, David, Costell, Brian, Delgado, Silvia, Fox, Edward, Gudesblatt, Mark, Gupta, Vipan, Harel, Asaff, Harrison, Daniel, Herrman, Craig, Honeycutt, William David, Hua, Le, Hunter, Samuel, Katsamakis, George, Kilgo, William, Koffman, Boyd, Lindsey, William, Lynch, Sharon G., Mateen, Farrah J., McAllister, Peter, Farahmand, Arya, Morales, Idanis Berrios, Rahmlow, Megan, Naismith, Robert, Napoli, Salvatore, Newman, Stephen, Pardo, Gabriel, Patel, Nirav, Scott, James, Purino, Lorraine, Vasquez, Alberto B., Weisman, David, Wray, Sibyl, Wynn, Daniel, Dihenia, Bhupesh, Obeidat, Ahmed, Ayala, Ricardo, Erwin, April, Betz, Michelle, DeAngelis, Teresa, Osborne Dusan Stefoski, Benjamin, Giang, Daniel, Hendin, Barry, Nagaraj, Arun, Saltis, Lawrence, Singer, Barry, Balabanov, Roumen, Bromley, Steven Michael, Puente, John, Tran, Duc, Kojan, Suleiman, Graves, Jennifer, Fishman, Simon, Maher, Leo, Londono, Diana, Sadiq, Mohamed, Alekseenko, Yuri, Fedulau, Aliaksandr, Kulesh, Sergey, Mikhailova, Elena, Navumava, Halina, Aragon deVecino, Maria Cecilia, Callegaro, Dagoberto, Daccach Marques, Vanessa, Finkelsztejn, Alessandro, Guerreiro, Alexandre, Kleinpaul, Rodrigo, Koiti Sato, Henry, Luiz Longo, Alexandre, Papais Alvarenga, Regina Maria, Pereira Damasceno, Benito, Pereira Gomes Neto, Antonio, Diniz Carneiro, Denise S., Tauil, Carlos Bernardo, Maciel Dias, Ronaldo, Olival, Guilherme, Zago Melo Dias, Paula, de Jesus Carvalho, Margarete, Sato, Douglas Kazutoshi, Forcelini, Cassiano Mateus, Pelov, Plamen, Haralanov, Lyubomir, Ikonomov, Rosen, Ivanov, Ivan, Kastrev, Sasho, Kirilov, Krasimir, Lilovski, Hristo, Maslarov, Dimitar, Staikov, Ivan, Zhelyazkov, Petko, Freedman, Mark, MacLean, Gregg, Marriott, James, McKelvey, John Roger, Girard, Jean-Marc, Vorobeychik, Galina, Morrow, Sarah, Clavelou, Pierre, de Seze, Jerome, Louapre, Celine, Maurousset, Aude, Ruet, Aurelie, Thouvenot, Eric, Morel, Nathalie, Montcuquet, Alexis, Rouhart, Francois, Angstwurm, Klemens, Bayas, Antonios, Bittner, Stefan, Heesen, Christoph, Kowarik, Markus, Marckmann-Boenke, Silke, Muller, Thomas, Zimmermann, Julian, Nelles, Gereon, Paul, Friedemann, Then Bergh, Florian, Wildemann, Brigitte, Zettl, Uwe Klaus, Ziemssen, Tjalf, Doerr, Jan-Marcus, Chroni, Elisabeth, Dardiotis, Efthymios, Doskas, Triantafyllos, Gatzonis, Stylianos, Grigoriadis, Nikolaos, Karageorgiou, Klimentini, Kouremenos, Evangelos, Mitsias, Panayiotis, Spengos, Konstantinos, Kimiskidis, Vasilios, Evangelopoulos, Maria E., Fakas, Nikolaos, Karanasios, Panagiotis, Kyritsis, Athanasios, Maltezou, Maria, Sotirli, Stefania, Tsolaki, Magda, Rohtagi, Anshu, Mukherjee, Joy, Nellikunja, Shankara, Srinivasa, Rangashetty, Sharma, Arvind, Chowdhury, Debashish, Kalita, Jayantee, Brescia Morra, Vincenzo, Centonze, Diego, Gasperini, Claudio, Grimaldi, Luigi, Maniscalco, Giorgia Teresa, Patti, Francesco, Salemi, Giuseppe, Trojano, Maria, Amato, Maria Pia, Malucchi, Simona, Brambilla, Laura, Pozzilli, Carlo, Al Roughani, Raed, Karelis, Guntis, Kalnina, Jolanta, Millers, Andrejs, Mickeviciene, Dalia, Giedraitiene, Natasa, Kazlauskas, Andrius, Malciene, Lina, Joseph, Joyce Pauline, Chung, Law Wan, Looi, Irene, Remli, Rabani, Binti Sapuan, Sapiah, Abdullah, Suhailah, Carbajal Ramirez, Angelica, Espino Ojeda, Alba, Silvestre Bejar Medina, Jesus, Quinones Aguilar, Sandra, Rivas Alonso, Veronica, de la Rosa, Rogelio Francisco, San Juan Orta, Daniel, Misic, Octavian, Odainic, Olesea, Torkildsen, Oivind, Schuler, Stephan, Broch, Line, Canete, Ma. Teresa, Hiyadan, John Harold, Hormillosa, Mary Pauline, Rosales, Raymond L., Adamczyk Sowa, Monika, Bartosik-Psujek, Halina, Berkowicz, Tomasz, Czarnecki, Maciej, Kłodowska, Gabriela, Klosek, Agata, Koscielniak, Jozef, Lisewski, Pawel, Mielcarek, Bartlomiej, Piasecka-Stryczynska, Karolina, Potemkowski, Andrzej, Stasiołek, Mariusz, Krzystanek, Ewa, Lasek-Bal, Anetta, Sikorska, Swietlana, Szczudlik, Andrzej, Gospodarczyk-Szot, Krystyna, Wierzchowska-Cioch, Ewa, K. Jastrzebska, Iwona, Capela, Carlos, Cerqueira, Joao, Correia, Ana Sofia, Correia, Filipe, Ferreira, Joaquim J., Gouveia, Raquel, Mendes, Irene, Nunes, Carla Cecilia, Timoteo, Angela, Veira, Carlos, Martins da Silva, Ana, Domingues, Joana, Chinea, Angel R, Tiu, Cristina, Balasa, Rodica, Chiru, Mirela, Dulamea, Adriana Octaviana, Silviu Manescu, Emilian, Mitrea, Dan, Mitu, Cristina, Nicolae, Silvia Maria, Filip, Carmen Corina Roman, Sabau, Monica, Vanghelie, Doinita, Varga, Ioana, Nunkoo, Vharoon, Agafina, Alina S., Gennadevna, Arefeva Elena, Alexeeva, Tatiana M., Bogdanov, Enver, Dorogov, Nikolay, Doronina, Olga, Goncharova, Zoya, Khasanova, Dina, Korobko, Denis, Pankratov, Evgeny V., Parshina, Elena, Poverennova, Irina, Prokopenko, Semyion V., Sazonov, Denis V., Shkilnyuk, Galina, Sivertseva, Stella, Stolyarov, Igor, Totolyan, Natalia A., Tsukurova, Larisa A., Vorobyeva, Olga V., Voznyuk, Igor A., Zakharova, Maria, Ardashev, Igor V., Boyko, Alexey, Alshehri, Ebtesam, Alkhawajah, Nuha M, Alfugham, Nora, Quek, Amy, Kevin, Tan, Dupejova, Beata, Feketova, Sona, Hancinova, Viera, Jurcaga, Frantisek, Turcani, Peter, Krastev, Georgi, Cimprichova, Andrea, Perichtova, Magdalena, Hojs-Fabjan, Tanja, Horvat Ledinek, Alenka, Savsek, Lina, Bateman, Kathleen, Frost, Andrew Charles, Henning, Franclo, Retief, Chris Francois, Aguado Valcarcel, Marta, Morales, Eduardo Aguera, Alonso Torres, Ana Maria, Borrega Canelo, Laura, Casanova Estruch, Bonaventura, Gascon Gimenez, Francisco, Ayuso, Guillermo I, Martinez Gines, Maria Luisa, Eustasio Meca Lallana, Jose, Rodriguez Antiguedad, Alfredo, Blasco Quilez, Rosario, Brieva Ruiz, Luis, Piehl, Fredrik, Lycke, Jan, Katsarogiannis, Evangelos, Nilsson, Christer, Hoepner, Robert, Zecca, Chiara, Findling, Oliver, Asawavichienjinda, Thanin, Kasemsap, Narongrit, Prayoonwiwat, Naraporn, Mhiri, Chokri, Ağan Yıldırım, Kadriye, Boz, Cavit, Efendi, Husnu, Soysal, Aysun, Terzi, Murat, Uygunoglu, Ugur, Gümüş, Haluk, Mungan, Semra, Ozakbas, Serkan, Serhan Sevim, Mustafa, Tamam, Yusuf, Kale, Nilufer, Karabudak, Rana, Bachinskaya, Natalia, Buchakchyiska, Nataliia, Chmyr, Galyna, Dzyak, Ludmyla, Ivashchenko, Svitlana, Kalbus, Oleksandr, Kareta, Serhiy, Korolova, Oksana, Kostiuchenko, Andrii, Kruchkevych, Zhanna, Larysa, Kadina, Mishchenko, Tamara, Moroz, Olena, Neryanova, Yuliya, Pasiura, Ihor, Pohrebnyak, Oleksandr, Pryshchepa, Volodymyr, Sanotskyy, Yanosh, Shkrobot, Svitlana, Shulga, Olga, Smolanka, Volodymyr, Tomakh, Nataliya, Zhuravlyova, Natalia, Allen, Alison B., Armstrong, Robert, Antezana, Ariel, Baker, Matthew, Bass, Ann, Benenati, Diana, Benson, Dalton, Beretich, Biljana, Burke, Deborah, Calkwood, Jonathan, Carpenter, Adam, Drake, Ryan, Dujmovic Basuroski, Irena, Gupta, Ajay, Hentati, Afif, Kaplan, Jeffrey, Katsafanas, Constance, Keegan, Andrew, Khatri, Bhupendra, Luzzio, Christopher, Malik, Maheen, Bennette, Myers, Miravalle, Augusto, Montoya, Liliana, Nash, Marshall, Poole Pharr, Emily, Sater, Richard A., Scagnelli, John, Schulman, Alan, Shafer, Stuart, Stein, Lee, Vandersluis, Joel, Williams, Armistead, Winkley, James, Berkovich, Regina, Cerghet, Mirela, Horton, Lindsay, Jacobs, Daniel H., Laurin, Nida, Liow, Kore, Robertson, Derrick, Mattson, David, Cabrera, Alicia V., Leist, Thomas, Negroski, Donald, Royter, Vladimir, LaGanke, Christopher, Winner, Paul, Sweeney, Michael, Weinberg, Lawrence A., Smith, Andrew, Rivas-Rodriguez, Erica, Wagner, Kimberly, Montalban, Xavier, Vermersch, Patrick, Arnold, Douglas L, Bar-Or, Amit, Cree, Bruce A C, Cross, Anne H, Kubala Havrdova, Eva, Kappos, Ludwig, Stuve, Olaf, Wiendl, Heinz, Wolinsky, Jerry S, Dahlke, Frank, Le Bolay, Claire, Shen Loo, Li, Gopalakrishnan, Sathej, Hyvert, Yann, Javor, Andrija, Guehring, Hans, Tenenbaum, Nadia, and Tomic, Davorka

Published
2024
Full Text
View/download PDF

7. Impact of Neuromyelitis Optica Spectrum Disorder on Quality of Life from the Patients’ Perspective: An Observational Cross-Sectional Study

Author

Meca-Lallana, José E., Gómez-Ballesteros, Rocío, Pérez-Miralles, Francisco, Forero, Lucía, Sepúlveda, María, Calles, Carmen, Martínez-Ginés, María L., González-Suárez, Inés, Boyero, Sabas, Romero-Pinel, Lucía, Sempere, Ángel P., Meca-Lallana, Virginia, Querol, Luis, Costa-Frossard, Lucienne, Prefasi, Daniel, and Maurino, Jorge

Published
2022
Full Text
View/download PDF

8. Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology

Author

Brieva, Luis, Estruch, Bonaventura Casanova, Merino, Juan Antonio García, Meca-Lallana, Virginia, Río, Jordi, Rodríguez-Antigüedad, Alfredo, Agüera, Eduardo, Ara, Jose Ramón, Luque, Adrián Arés, Garcia, Carmen Arnal, Blanco, Yolanda, Castillo-Triviño, Tamara, Costa-Frossard, Lucienne, González Platas, Montserrat, Pascual, Lamberto Landete, Llaneza-González, Miguel, Ginés, María Luisa Martínez, Matías-Guiu, Jorge, Meca-Lallana, José E, Bilbao, Mar Mendibe, Sempere, Angel Pérez, Romero-Pinel, Lucia, Saiz, Albert, and Moral, Ester

Published
2022
Full Text
View/download PDF

9. Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis.

Author

Rodríguez-Jorge, Fernando, Fernández-Velasco, José Ignacio, Villarrubia, Noelia, Gracia-Gil, Julia, Fernández, Eva, Meca-Lallana, Virginia, Díaz-Pérez, Carolina, Sainz de la Maza, Susana, Pacheco, Eva María, Quiroga, Ana, Ramió-Torrentà, Lluis, Martínez-Yélamos, Sergio, Bau, Laura, Monreal, Enric, López-Real, Ana, Rodero-Romero, Alexander, Borrega, Laura, Díaz, Santiago, Eguía, Pablo, and Espiño, Mercedes

Subjects
GLIAL fibrillary acidic protein, BODY mass index, MULTIPLE sclerosis, DISEASE progression, CYTOPLASMIC filaments
Abstract

Objective: To ascertain the changes of serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) values in relapsing–remitting multiple sclerosis (RRMS) patients treated with ocrelizumab and their association with treatment response. Methods: Multicenter prospective study including 115 RRMS patients initiating ocrelizumab treatment between February 2020 and March 2022 followed during a year. Serum samples were collected at baseline and every 3 months to measure sNfL and sGFAP levels using single-molecule array (SIMOA) technology. Based on age and body mass index, sNfL values were standardized using z-score. NEDA (non-evidence of disease activity)-3 status was defined for patients free of disease activity after a year of follow-up. Inflammation (INFL) was considered when new relapses occurred during follow-up or new MRI lesions were found at 1-year exploration. PIRA (progression independent of relapse activity) was defined as disability progression occurring in the absence of relapses or new MRI activity. Results: After a year on ocrelizumab, 85 patients (73.9%) achieved NEDA-3. Thirty patients did not achieve NEDA: 20 (17.4%) because of INFL and 10 (8.7%) because of PIRA. Of INFL patients, 6 (30.0%) had relapses, and 17 (85.0%) had at least one new MRI lesion at the 12-month examination. At baseline, INFL patients had higher sNfL (p = 0.0003) and sGFAP (p = 0.03) than the NEDA-3 group. PIRA patients mostly exhibited low sNfL and heterogeneous sGFAP levels. After a year, NEDA-3 and INFL patients showed similar decreases in sNfL (p < 0.0001) and sGFAP (p < 0.0001 for NEDA-3 and p = 0.001 for INFL ones). However, the decrease occurred earlier in NEDA-3 patients. Accordingly, sNfL > 1.5 z-score 3 months after ocrelizumab initiation indicated a higher risk of inflammation (OR = 13.6; p < 0.0001). Decrease in sGFAP values occurred later in both groups, with significant reductions observed at 12 months for INFL and 6 and 12 months for NEDA-3. No significant changes in sNfL or sGFAP were observed in PIRA patients. Conclusion: Ocrelizumab induced normalization of sNfL and sGFAP in the majority of NEDA-3 and inflammatory patients but did not cause changes in the PIRA group. Our data suggest that normalization of sNfL and sGFAP is associated with the lack of inflammatory-associated disease progression but it may not affect non-inflammatory PIRA. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

10. Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis.

Author

Rodríguez-Jorge, Fernando, Fernández-Velasco, José Ignacio, Villarrubia, Noelia, Gracia-Gil, Julia, Fernández, Eva, Meca-Lallana, Virginia, Díaz-Pérez, Carolina, Sainz de la Maza, Susana, Pacheco, Eva María, Quiroga, Ana, Ramió-Torrentà, Lluis, Martínez-Yélamos, Sergio, Bau, Laura, Monreal, Enric, López-Real, Ana, Rodero-Romero, Alexander, Borrega, Laura, Díaz, Santiago, Eguía, Pablo, and Espiño, Mercedes

Subjects
GLIAL fibrillary acidic protein, BODY mass index, MULTIPLE sclerosis, DISEASE progression, CYTOPLASMIC filaments
Abstract

Objective: To ascertain the changes of serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) values in relapsing–remitting multiple sclerosis (RRMS) patients treated with ocrelizumab and their association with treatment response. Methods: Multicenter prospective study including 115 RRMS patients initiating ocrelizumab treatment between February 2020 and March 2022 followed during a year. Serum samples were collected at baseline and every 3 months to measure sNfL and sGFAP levels using single-molecule array (SIMOA) technology. Based on age and body mass index, sNfL values were standardized using z-score. NEDA (non-evidence of disease activity)-3 status was defined for patients free of disease activity after a year of follow-up. Inflammation (INFL) was considered when new relapses occurred during follow-up or new MRI lesions were found at 1-year exploration. PIRA (progression independent of relapse activity) was defined as disability progression occurring in the absence of relapses or new MRI activity. Results: After a year on ocrelizumab, 85 patients (73.9%) achieved NEDA-3. Thirty patients did not achieve NEDA: 20 (17.4%) because of INFL and 10 (8.7%) because of PIRA. Of INFL patients, 6 (30.0%) had relapses, and 17 (85.0%) had at least one new MRI lesion at the 12-month examination. At baseline, INFL patients had higher sNfL (p = 0.0003) and sGFAP (p = 0.03) than the NEDA-3 group. PIRA patients mostly exhibited low sNfL and heterogeneous sGFAP levels. After a year, NEDA-3 and INFL patients showed similar decreases in sNfL (p < 0.0001) and sGFAP (p < 0.0001 for NEDA-3 and p = 0.001 for INFL ones). However, the decrease occurred earlier in NEDA-3 patients. Accordingly, sNfL > 1.5 z-score 3 months after ocrelizumab initiation indicated a higher risk of inflammation (OR = 13.6; p < 0.0001). Decrease in sGFAP values occurred later in both groups, with significant reductions observed at 12 months for INFL and 6 and 12 months for NEDA-3. No significant changes in sNfL or sGFAP were observed in PIRA patients. Conclusion: Ocrelizumab induced normalization of sNfL and sGFAP in the majority of NEDA-3 and inflammatory patients but did not cause changes in the PIRA group. Our data suggest that normalization of sNfL and sGFAP is associated with the lack of inflammatory-associated disease progression but it may not affect non-inflammatory PIRA. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Short-term data on disease activity, cognition, mood, stigma and employment outcomes in a cohort of patients with primary progressive multiple sclerosis (UPPMS study)

Author

Pérez-Miralles, Francisco, Prefasi, Daniel, García-Merino, Antonio, Ara, José Ramón, Izquierdo, Guillermo, Meca-Lallana, Virginia, Gascón-Giménez, Francisco, Martínez-Ginés, María Luisa, Ramió-Torrentà, Lluis, Costa-Frossard, Lucienne, Fernández, Óscar, Moreno-García, Sara, Medrano, Nicolás, Maurino, Jorge, and Casanova, Bonaventura

Published
2021
Full Text
View/download PDF

13. Beyond lines of treatment: embracing early high-efficacy disease-modifying treatments for multiple sclerosis management.

Author

Oreja-Guevara, Celia, Martínez-Yélamos, Sergio, Eichau, Sara, Llaneza, Miguel Ángel, Martín-Martínez, Jesús, Peña-Martínez, Joaquín, Meca-Lallana, Virginia, Alonso-Torres, Ana María, Moral-Torres, Ester, Río, Jordi, Calles, Carmen, Ares-Luque, Adrián, Ramió-Torrentà, Lluís, Marzo-Sola, María Eugenia, Prieto, José María, Martínez-Ginés, María Luisa, Arroyo, Rafael, Otano-Martínez, María Ángeles, Brieva-Ruiz, Luis, and Gómez-Gutiérrez, Montserrat

Subjects
MAGNETIC resonance imaging, RANDOMIZED controlled trials, MULTIPLE sclerosis, TREATMENT effectiveness, DISEASE progression
Abstract

Recent advances in multiple sclerosis (MS) management have shifted perspectives on treatment strategies, advocating for the early initiation of high-efficacy disease-modifying therapies (heDMTs). This perspective review discusses the rationale, benefits, and challenges associated with early heDMT initiation, reflecting on the obsolescence of the traditional "first-line" and "second-line" treatment classifications. The article emerges from the last update of the consensus document of the Spanish Society of Neurology on the treatment of MS. During its development, there was a recognized need to further discuss the concept of treatment lines and the early use of heDMTs. Evidence from randomized controlled trials and real-world studies suggests that early heDMT initiation leads to improved clinical outcomes, including reduced relapse rates, slowed disease progression, and decreased radiological activity, especially in younger patients or those in early disease stages. Despite the historical belief that heDMTs involve more risks and adverse events compared to moderate-efficacy DMTs (meDMTs), some studies have reported comparable safety profiles between early heDMTs and meDMTs, though long-term safety data are still lacking. The review also addresses the need for a personalized approach based on patient characteristics, prognostic factors, and preferences, explores the importance of therapeutic inertia, and highlights the evolving landscape of international and national guidelines that increasingly advocate for early intensive treatment approaches. The article also addresses the challenges of ensuring access to these therapies and the importance of further research to establish long-term safety and effectiveness of DMTs in MS. Plain language summary: Choosing stronger treatments early on for better multiple sclerosis care Recent progress in treating multiple sclerosis (MS) has changed how doctors think about starting treatments, with more support now for using high-efficacy disease-modifying treatments (heDMTs) early on. This article talks about why starting heDMTs early can be good, what benefits it might bring, and what challenges there might be. It also mentions how the old way of categorizing treatments into "first-line" and "second-line" is becoming outdated. This discussion is based on the latest recommendations from the Spanish Society of Neurology. The article explains that starting heDMTs early can lead to better results for patients, like fewer relapses, slower progression of the disease, and less damage seen on magnetic resonance imaging (MRI). This is particularly true for younger patients or those who are in the early stages of MS. Even though there was a concern that these heDMTs might have more side effects compared to other treatments, recent studies show that they could be just as safe, though more research is needed to be sure about their safety in the long run. The review suggests that treatment should be tailored to each patient, considering their specific situation, what they prefer, and the urgency to start treatment. It also discusses the need to overcome delays in starting these treatments and how treatment guidelines are changing to support starting strong treatments earlier. Finally, the article points out that it is still important to make these treatments accessible to everyone who needs them and to keep researching to understand their long-term safety and effectiveness. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Multiple Sclerosis Treatment and Holistic Patient Care Consensus by the Spanish Society of Neurology (P3-6.013)

Author

Meca Lallana, José E., primary, Yélamos, Sergio Martínez, additional, Madueno, Sara Eichau, additional, Llaneza, Miguel Ángel, additional, Martínez, Jesús Martín, additional, Peña-Martínez, Joaquín, additional, Meca-Lallana, Virginia, additional, Torres, Ana María Alonso, additional, Torres, Ester Moral, additional, Río, Jordi, additional, Calles, Carmen, additional, Luque, Adrián Ares, additional, Torrenta, Lluis Ramio, additional, Sola, María Eugenia Marzo, additional, Prieto, José María, additional, Ginés, María Luisa Martínez, additional, Gonzalez, Rafael Arroyo, additional, Martínez, María Ángeles Otano, additional, Ruiz, Luis Brieva, additional, Guitiérrez, Montserrat Gómez, additional, Zarranz, Alfredo Rodríguez-Antigüedad, additional, Seco, Victoria Galán Sánchez, additional, Costa-Frossard, Lucienne, additional, Pérez, Miguel Ángel Hernández, additional, Landete-Pascual, Lamberto, additional, Platas, Montserrat Gonzalez, additional, and Oreja-Guevara, Celia, additional

Published
2024
Full Text
View/download PDF

16. Multi-centre validation of a flow cytometry method to identify optimal responders to interferon-beta in multiple sclerosis

Author

Villarrubia, Noelia, Rodríguez-Martín, Eulalia, Alari-Pahissa, Elisenda, Aragón, Larraitz, Castillo-Triviño, Tamara, Eixarch, Herena, Ferrer, Joana María, Martínez-Rodríguez, José Enrique, Massot, Margarita, Pinto-Medel, María Jesús, Prada, Álvaro, Rodríguez-Acevedo, Breogán, Urbaneja, Patricia, Gascón-Gimenez, Francisco, Herrera, Guadalupe, Hernández-Clares, Rocío, Salgado, María Gema, Oterino, Agustín, San Segundo, David, Cuello, Juan Pablo, Gil-Herrera, Juana, Cámara, Carmen, Gómez-Gutiérrez, Montserrat, Martínez-Hernández, Eugenia, Meca-Lallana, Virginia, Moga, Esther, Muñoz-Calleja, Cecilia, Querol, Luis, Presas-Rodríguez, Silvia, Teniente-Serra, Aina, Vlagea, Alexandru, Muriel, Alfonso, Roldán, Ernesto, and Villar, Luisa María

Published
2019
Full Text
View/download PDF

17. SARS-CoV-2 Infection in Multiple Sclerosis: Results of the Spanish Neurology Society Registry

Author

Arrambide, Georgina, Llaneza-González, Miguel Ángel, Costa-Frossard França, Lucienne, Meca-Lallana, Virginia, Díaz, Eva Fernández-, Moreno-Torres, Irene, García-Domínguez, Jose Manuel, Ortega-Suero, Gloria, Ayuso-Peralta, Lucía, Gómez-Moreno, Mayra, Sotoca-Fernández, Javier J., Caminero-Rodríguez, Ana Belén, Rodríguez de Antonio, Luis A., Corujo-Suárez, Marcial, Otano-Martínez, María A., Pérez-Miralles, Francisco Carlos, Reyes-Garrido, Virginia, Ayuso-Blanco, Teresa, Balseiro-Gómez, José Jesús, Muñoz-Pasadas, Mercedes, Pérez-Molina, Inmaculada, Arnal-García, Carmen, Domingo-Santos, Ángela, Guijarro-Castro, Cristina, Íñiguez-Martínez, Cristina, Téllez Lara, Nieves, Castellanos-Pinedo, Fernando, Castillo-Triviño, Tamara, Cerdán-Santacruz, Debora María, Pérez-Sempere, Ángel, Torres, Berta Sebastián, Álvarez de Arcaya, Amaya, Costa-Arpín, Eva, Durán-Ferreras, Eduardo, Fragoso-Martínez, Marta, González-Platas, Montserrat, Landete Pascual, Lamberto, Millán-Pascual, Jorge, Oreja-Guevara, Celia, and Meca-Lallana, José E.

Published
2021
Full Text
View/download PDF

19. Anti-JC virus seroprevalence in a Spanish multiple sclerosis cohort: JC virus seroprevalence in Spain

Author

Aladro, Yolanda, Terrero, Rodrigo, Cerezo, Marta, Ginestal, Ricardo, Ayuso, Lucía, Meca-Lallana, Virginia, Millán, Jorge, Borrego, Laura, Martinez-Ginés, Marisa, Rubio, Luisa, de Andrés, Clara, Miralles, Ambrosio, Guijarro, Cristina, Rodríguez-García, Elena, García-Dominguez, José Manuel, Muñoz-Fernández, Carmen, López de Silanes, Carlos, Gómez, Mayra, Thuissard, Israel, Cerdán, María, Palmí, Itziar, Díaz-Garzón, Luis Felipe, and Meca-Lallana, Jose

Published
2016
Full Text
View/download PDF

20. Corrigendum: Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis.

Author

Rodríguez-Jorge, Fernando, Fernández-Velasco, José Ignacio, Villarrubia, Noelia, Gracia-Gil, Julia, Fernández, Eva, Meca-Lallana, Virginia, Díaz-Pérez, Carolina, Sainz de la Maza, Susana, Pacheco, Eva María, Quiroga, Ana, Ramió-Torrentà, Lluis, Martínez-Yélamos, Sergio, Bau, Laura, Monreal, Enric, López-Real, Ana, Rodero-Romero, Alexander, Borrega, Laura, Díaz, Santiago, Eguía, Pablo, and Espiño, Mercedes

Subjects
GLIAL fibrillary acidic protein, BLOOD proteins, MULTIPLE sclerosis, SCHOLARLY periodical corrections, CYTOPLASMIC filaments
Abstract

The correction notice in the journal "Frontiers in Immunology" addresses an error in the spelling of an author's name, correcting "Fernando Castellanos" to "Fernando Castellanos-Pinedo." The authors acknowledge the mistake but clarify that it does not impact the scientific conclusions of the article. The document lists all authors involved in the study on biomarkers of response to ocrelizumab in relapsing-remitting multiple sclerosis. [Extracted from the article]

Published
2025
Full Text
View/download PDF

21. XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (II)

Author

Fernández Fernández, Óscar, primary, Montalban Gairin, Xavier, additional, Agüera Morales, Eduardo, additional, Aladro Benito, Yolanda, additional, Alonso, Ana, additional, Arroyo González, Rafael V., additional, Brieva Ruiz, Lluís, additional, Calles Hernández, Mª Carmen, additional, Costa-Frossard França, Lucienne, additional, Eichau Madueño, Sara, additional, García Domínguez, José Manuel, additional, Hernández Pérez, Miguel Ángel, additional, Landete Pascual, Lamberto, additional, Llaneza González, Miguel A., additional, Llufriu Durán, Sara, additional, Meca Lallana, José Eustasio, additional, Meca Lallana, Virginia, additional, Mongay Ochoa, Neus, additional, Moral, Ester, additional, Oreja Guevara, Celia, additional, Ramió Torrentà, Lluís, additional, Téllez Lara, Nieves, additional, Romero Pinel, Lucía, additional, and Rodríguez Antigüedad, Alfredo, additional

Published
2023
Full Text
View/download PDF

23. Cognitive performance and health-related quality of life in patients with neuromyelitis optica spectrum disorder (P16-4.006)

Author

Lopez-Soley, Elisabet, primary, Llufriu, Sara, additional, Gómez-Ballesteros, Rocío, additional, Mauriño, Jorge, additional, Pérez-Miralles, Francisco, additional, Forero, Lucía, additional, Sepúlveda, María, additional, Calles, Carmen, additional, Gines, Maria Luisa Martinez, additional, Gonzalez, Ines, additional, Boyero, Sabas, additional, Romero-Pinel, Lucía, additional, Sempere, Ángel P., additional, Meca-Lallana, Virginia, additional, Querol, Luis, additional, Franca, Lucienne Costa, additional, Saiz, Albert, additional, Meca-Lallana, Jose E., additional, and Solana, Elisabeth, additional

Published
2022
Full Text
View/download PDF

24. Cognitive Performance and Health-Related Quality of Life in Patients with Neuromyelitis Optica Spectrum Disorder

Author

Lopez-Soley, Elisabet, primary, Meca-Lallana, Jose E., additional, Llufriu, Sara, additional, Blanco, Yolanda, additional, Gómez-Ballesteros, Rocío, additional, Maurino, Jorge, additional, Pérez-Miralles, Francisco, additional, Forero, Lucía, additional, Calles, Carmen, additional, Martinez-Gines, María L., additional, Gonzalez-Suarez, Inés, additional, Boyero, Sabas, additional, Romero-Pinel, Lucía, additional, Sempere, Ángel P., additional, Meca-Lallana, Virginia, additional, Querol, Luis, additional, Costa-Frossard, Lucienne, additional, Sepulveda, Maria, additional, and Solana, Elisabeth, additional

Published
2022
Full Text
View/download PDF

25. Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology

Author

Fernández-Velasco, José I., primary, Monreal, Enric, additional, Kuhle, Jens, additional, Meca-Lallana, Virginia, additional, Meca-Lallana, José, additional, Izquierdo, Guillermo, additional, Oreja-Guevara, Celia, additional, Gascón-Giménez, Francisco, additional, Sainz de la Maza, Susana, additional, Walo-Delgado, Paulette E., additional, Lapuente-Suanzes, Paloma, additional, Maceski, Aleksandra, additional, Rodríguez-Martín, Eulalia, additional, Roldán, Ernesto, additional, Villarrubia, Noelia, additional, Saiz, Albert, additional, Blanco, Yolanda, additional, Diaz-Pérez, Carolina, additional, Valero-López, Gabriel, additional, Diaz-Diaz, Judit, additional, Aladro, Yolanda, additional, Brieva, Luis, additional, Íñiguez, Cristina, additional, González-Suárez, Inés, additional, Rodríguez de Antonio, Luis A, additional, García-Domínguez, José M., additional, Sabin, Julia, additional, Llufriu, Sara, additional, Masjuan, Jaime, additional, Costa-Frossard, Lucienne, additional, and Villar, Luisa M., additional

Published
2022
Full Text
View/download PDF

26. Impact of neuromyelitis optica spectrum disorder on quality of life: Assessing the patients' perspective

Author

Meca-Lallana, José, Gómez-Ballesteros, Rocío, Pérez-Miralles, Francisco, Forero, Lucía, Sepúlveda, María, Calles, Carmen, Martínez-Ginés, María Luisa, González-Suárez, Inés, Boyero, Sabas, Romero-Pinel, Lucía, Sempere, Angel P., Meca-Lallana, Virginia, Querol, Luis, Costa-Frossard, Lucienne, Prefasi, Daniel, and Mauriño, Jorge

Published
2021
Full Text
View/download PDF

28. Analysis of Humoral and Cellular Immunity after SARS-CoV-2 Vaccination in Patients with Multiple Sclerosis Treated with Immunomodulatory Drugs

Author

Meca-Lallana, Virginia, primary, Esparcia Pinedo, Laura, additional, Aguirre, Clara, additional, Díaz-Pérez, Carolina, additional, Gutierrez-Cobos, Ainhoa, additional, Sobrado, Mónica, additional, Carabajal, Estefanía, additional, del Río, Beatriz, additional, Ropero, Noelia, additional, Villagrasa, Ramón, additional, Vivancos, José, additional, Sanchez-Madrid, Francisco, additional, and Alfranca, Arantzazu, additional

Published
2022
Full Text
View/download PDF

29. Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry

Author

Meca-Lallana, J. E., Oreja-Guevara, C., Muñoz, D., Olascoaga, J., Pato, A., Ramió-Torrentà, L., Meca-Lallana, Virginia, Hernández, M. A., Marzo, M. E., Álvarez- Cermeño, J. C., Rodríguez-Antigüedad, A., Montalban, Xavier, Fernández, O., Universitat Autònoma de Barcelona. Departament de Medicina, Institut Català de la Salut, [Meca-Lallana JE] Neurology Department, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain. [Oreja-Guevara C] Neurology Department, Hospital Clínico San Carlos, Madrid, Spain. [Muñoz D] Neurology Department, Hospital Xeral de Vigo, Vigo, Spain. [Olascoaga J] Neurology Department, Hospital Universitario Donostia, San Sebastián, Spain. [Pato A] Neurology Department, Hospital Povisa, Vigo, Spain. [Ramió-Torrentà L] Neurology Department, Hospital Universitari de Girona Dr. Josep Trueta, IDIBGI, Medical Sciences Department, University of Girona, Girona, Spain. [Montalbán X] Servei de Neurologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, Westerdijk Fungal Biodiversity Institute, and Westerdijk Fungal Biodiversity Institute - Evolutionary Phytopathology

Subjects
Male, European People, Medicaments immunosupressors - Ús terapèutic - Efectes secundaris, Spanish People, Drug research and development, Other subheadings::Other subheadings::/drug therapy [Other subheadings], Biochemistry, Medical Conditions, Clinical trials, Natalizumab, Recurrence, Medicine and Health Sciences, Ethnicities, Registries, Hispanic People, education.field_of_study, Multidisciplinary, Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis [DISEASES], Neurodegenerative Diseases, Middle Aged, Fingolimod, Phase III clinical investigation, Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Immunologic Factors::Immunosuppressive Agents [CHEMICALS AND DRUGS], Treatment Outcome, Neurology, Research Design, enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple [ENFERMEDADES], Medicine, Female, Immunosuppressive Agents, Research Article, medicine.drug, Adult, medicine.medical_specialty, Multiple Sclerosis, Clinical Research Design, Science, Urinary system, Immunology, Population, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Autoimmune Diseases, Signs and Symptoms, Adverse Reactions, Lymphopenia, Internal medicine, medicine, Humans, Glatiramer acetate, education, Adverse effect, Retrospective Studies, Pharmacology, Fingolimod Hydrochloride, business.industry, Multiple sclerosis, Biology and Life Sciences, Proteins, diagnóstico::pronóstico::resultado del tratamiento [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], medicine.disease, Demyelinating Disorders, Research and analysis methods, Spain, People and Places, Lesions, Avaluació de resultats (Assistència sanitària), Clinical Immunology, Population Groupings, Observational study, Interferons, Adverse Events, Clinical Medicine, business, Esclerosi múltiple - Tractament, acciones y usos químicos::acciones farmacológicas::efectos fisiológicos de los fármacos::factores inmunitarios::inmunosupresores [COMPUESTOS QUÍMICOS Y DROGAS]
Abstract

Esclerosis múltiple; Reacciones adversas; Infecciones respiratorias Esclerosi múltiple; Reaccions adverses; Infeccions respiratòries Multiple sclerosis; Adverse reactions; Respiratory infections Objective To describe the profile of patients with multiple sclerosis (MS) treated with fingolimod in Spain and to assess the effectiveness and safety of fingolimod after 4 years of inclusion in the Spanish Gilenya Registry. Methods An observational, retrospective/prospective, multicenter case registry, including all patients with relapsing-remitting MS (RRMS) starting treatment with fingolimod in 43 centers in Spain. Analyses were performed in the overall population and in subgroups according to prior disease-modifying therapy (DMT): glatiramer acetate/interferon beta-1 (BRACE), natalizumab, other treatment, or naïve. Results Six hundred and sixty-six evaluable patients were included (91.1% previously treated with at least one DMT). The mean annualized relapse rate (ARR) prior to fingolimod was 1.12, and the mean EDSS at fingolimod initiation was 3.03. Fingolimod reduced the ARR by 71.4%, 75%, 75.5%, and 80.3%, after 1, 2, 3 and 4 years, respectively (p

Published
2021

33. Deciphering Multiple Sclerosis Progression

Author

Meca-Lallana, Virginia, Berenguer-Ruiz, Leticia, Carreres-Polo, Joan, Eichau-Madueno, Sara, Ferrer-Lozano, Jaime, Forero, Lucia, Higueras, Yolanda, Tellez Lara, Nieves, Vidal-Jordana, Angela, and Perez-Miralles, Francisco Carlos

Subjects
progressive multiple sclerosis, neurodegeneration, neurofilament, multiple sclerosis, MRI
Abstract

Multiple sclerosis (MS) is primarily an inflammatory and degenerative disease of the central nervous system, triggered by unknown environmental factors in patients with predisposing genetic risk profiles. The prevention of neurological disability is one of the essential goals to be achieved in a patient with MS. However, the pathogenic mechanisms driving the progressive phase of the disease remain unknown. It was described that the pathophysiological mechanisms associated with disease progression are present from disease onset. In daily practice, there is a lack of clinical, radiological, or biological markers that favor an early detection of the disease's progression. Different definitions of disability progression were used in clinical trials. According to the most descriptive, progression was defined as a minimum increase in the Expanded Disability Status Scale (EDSS) of 1.5, 1.0, or 0.5 from a baseline level of 0, 1.0-5.0, and 5.5, respectively. Nevertheless, the EDSS is not the most sensitive scale to assess progression, and there is no consensus regarding any specific diagnostic criteria for disability progression. This review document discusses the current pathophysiological concepts associated with MS progression, the different measurement strategies, the biomarkers associated with disability progression, and the available pharmacologic therapeutic approaches.

Published
2021

34. SARS-CoV-2 Infection in Multiple Sclerosis

Author

Arrambide, Georgina, Llaneza-González, Miguel Ángel, Costa-Frossard França, Lucienne, Meca-Lallana, Virginia, Díaz, Eva Fernández, Moreno-Torres, Irene, García-Domínguez, Jose Manuel, Ortega-Suero, Gloria, Ayuso-Peralta, Lucía, Gómez-Moreno, Mayra, Sotoca Fernández, Javier, Caminero-Rodríguez, Ana Belén, Rodríguez de Antonio, Luis A., Corujo-Suárez, Marcial, Otano-Martínez, María A., Pérez-Miralles, Francisco Carlos, Reyes-Garrido, Virginia, Ayuso-Blanco, Teresa, Balseiro-Gómez, José, Muñoz-Pasadas, Mercedes, Pérez-Molina, Inmaculada, Domingo-Santos, Ángela, Guijarro-Castro, Cristina, Íñiguez-Martínez, Cristina, Téllez Lara, Nieves, Castellanos-Pinedo, Fernando, Castillo-Triviño, Tamara, Cerdán-Santacruz, Debora María, Torres, Berta Sebastián, Álvarez de Arcaya, Amaya, Costa-Arpín, Eva, Durán-Ferreras, Eduardo, González-Platas, Montserrat, Landete Pascual, Lamberto, Millán-Pascual, Jorge, Oreja-Guevara, Celia, and Universitat Autònoma de Barcelona

Abstract

To understand COVID-19 characteristics in people with multiple sclerosis (MS) and identify high-risk individuals due to their immunocompromised state resulting from the use of disease-modifying treatments. Retrospective and multicenter registry in patients with MS with suspected or confirmed COVID-19 diagnosis and available disease course (mild = ambulatory; severe = hospitalization; and critical = intensive care unit/death). Cases were analyzed for associations between MS characteristics and COVID-19 course and for identifying risk factors for a fatal outcome. Of the 326 patients analyzed, 120 were cases confirmed by real-time PCR, 34 by a serologic test, and 205 were suspected. Sixty-nine patients (21.3%) developed severe infection, 10 (3%) critical, and 7 (2.1%) died. Ambulatory patients were higher in relapsing MS forms, treated with injectables and oral first-line agents, whereas more severe cases were observed in patients on pulsed immunosuppressors and critical cases among patients with no therapy. Severe and critical infections were more likely to affect older males with comorbidities, with progressive MS forms, a longer disease course, and higher disability. Fifteen of 33 patients treated with rituximab were hospitalized. Four deceased patients have progressive MS, 5 were not receiving MS therapy, and 2 were treated (natalizumab and rituximab). Multivariate analysis showed age (OR 1.09, 95% CI, 1.04-1.17) as the only independent risk factor for a fatal outcome. This study has not demonstrated the presumed critical role of MS therapy in the course of COVID-19 but evidenced that people with MS with advanced age and disease, in progressive course, and those who are more disabled have a higher probability of severe and even fatal disease

Published
2021

35. Quantifying the patient´s perspective in neuromyelitis optica spectrum disorder: Psychometric properties of the SymptoMScreen questionnaire

Author

Meca-Lallana, José E., primary, Maurino, Jorge, additional, Pérez-Miralles, Francisco, additional, Forero, Lucía, additional, Sepúlveda, María, additional, Calles, Carmen, additional, Martínez-Ginés, María L., additional, González-Suárez, Inés, additional, Boyero, Sabas, additional, Romero-Pinel, Lucía, additional, Sempere, Ángel P., additional, Meca-Lallana, Virginia, additional, Querol, Luis, additional, Costa-Frossard, Lucienne, additional, Prefasi, Daniel, additional, Gómez-Ballesteros, Rocío, additional, and Ballesteros, Javier, additional

Published
2021
Full Text
View/download PDF

36. Risk and outcomes of COVID‐19 in patients with multiple sclerosis

Author

Moreno‐Torres, Irene, primary, Meca Lallana, Virginia, additional, Costa‐Frossard, Lucienne, additional, Oreja‐Guevara, Celia, additional, Aguirre, Clara, additional, Alba Suárez, Elda María, additional, Gómez Moreno, Mayra, additional, Borrega Canelo, Laura, additional, Sabín Muñoz, Julia, additional, Aladro, Yolanda, additional, Cárcamo, Alba, additional, Rodríguez García, Elena, additional, Cuello, Juan Pablo, additional, Monreal, Enric, additional, Sainz de la Maza, Susana, additional, Pérez Parra, Fernando, additional, Valenzuela Rojas, Francisco, additional, López de Silanes de Miguel, Carlos, additional, Casanova, Ignacio, additional, Martínez Gines, Maria Luisa, additional, Blasco, Rosario, additional, Orviz García, Aida, additional, Villar‐Guimerans, Luisa María, additional, Fernández‐Dono, Guillermo, additional, Elvira, Víctor, additional, Santiuste, Carmen, additional, Espiño, Mercedes, additional, and García Domínguez, José Manuel, additional

Published
2021
Full Text
View/download PDF

37. Quantifying the patients perspective in neuromyelitis optica spectrum disorder: Psychometric properties of the SymptoMScreen questionnaire

Author

Neurociencias, Neurozientziak, Meca Lallana, José E., Maurino, Jorge, Pérez Miralles, Francisco, Forero, Lucía, Sepúlveda, María, Calles, Carmen, Martínez Ginés, María L., González Suárez, Inés, Boyero, Sabas, Romero Pinel, Lucía, Sempere, Ángel P., Meca Lallana, Virginia, Querol, Luis, Costa Frossard, Lucienne, Prefasi, Daniel, Gómez Ballesteros, Rocío, Ballesteros Rodríguez, Francisco Javier, Neurociencias, Neurozientziak, Meca Lallana, José E., Maurino, Jorge, Pérez Miralles, Francisco, Forero, Lucía, Sepúlveda, María, Calles, Carmen, Martínez Ginés, María L., González Suárez, Inés, Boyero, Sabas, Romero Pinel, Lucía, Sempere, Ángel P., Meca Lallana, Virginia, Querol, Luis, Costa Frossard, Lucienne, Prefasi, Daniel, Gómez Ballesteros, Rocío, and Ballesteros Rodríguez, Francisco Javier

Abstract

BACKGROUND: The assessment of self-reported outcomes in neuromyelitis optica spectrum disorder (NMOSD) is limited by the lack of validated disease-specific measures. The SymptoMScreen (SyMS) is a patient-reported questionnaire for measuring symptom severity in different domains affected by multiple sclerosis (MS), but has not been thoroughly evaluated in NMOSD. The aim of this study was to assess the psychometric properties of the SyMS in a sample of patients with NMOSD. METHODS: A non-interventional, cross-sectional study in adult subjects with NMOSD (Wingerchuk 2015 criteria) was conducted at 13 neuroimmunology clinics applying the SyMS. A non-parametric item response theory procedure, Mokken analysis, was performed to assess the underlying dimensional structure and scalability of items and overall questionnaire. All analyses were performed with R (v4.0.3) using the mokken library. RESULTS: A total of 70 patients were studied (mean age: 47.5 ± 15 years, 80% female, mean Expanded Disability Status Scale score: 3.0 [interquartile range 1.5, 4.5]). Symptom severity was low (median SyMS score: 19.0 [interquartile range 10.0, 32.0]). The SyMS showed a robust internal reliability (Cronbach's alpha: 0.90 [95% confidence interval 0.86, 0.93]) and behaved as a unidimensional scale with all items showing scalability coefficients > 0.30. The overall SyMS scalability was 0.45 conforming to a medium scale according to Mokken's criteria. Fatigue and body pain were the domains with the highest scalability coefficients. The SyMS was associated with disability (rho: 0.586), and physical and psychological quality of life (rho: 0.856 and 0.696, respectively). CONCLUSIONS: The SyMS shows appropriate psychometric characteristics and may constitute a valuable and easy-to-implement option to measure symptom severity in patients with NMOSD.

Published
2021

38. Perception of Stigma in Patients with Neuromyelitis Optica Spectrum Disorder

Author

Meca-Lallana, Jose E, primary, Prefasi, Daniel, additional, Pérez-Miralles, Francisco, additional, Forero, Lucía, additional, Sepúlveda, María, additional, Calles, Carmen, additional, Martínez-Ginés, María L, additional, González-Suárez, Inés, additional, Boyero, Sabas, additional, Romero-Pinel, Lucía, additional, Sempere, Ángel P, additional, Meca-Lallana, Virginia, additional, Querol, Luis, additional, Costa-Frossard, Lucienne, additional, de Castro-Trapiello, Hugo, additional, Canal, Neus, additional, and Maurino, Jorge, additional

Published
2021
Full Text
View/download PDF

39. Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS

Author

Fernández-Velasco, José I., primary, Kuhle, Jens, additional, Monreal, Enric, additional, Meca-Lallana, Virginia, additional, Meca-Lallana, José, additional, Izquierdo, Guillermo, additional, Gascón-Giménez, Francisco, additional, Sainz de la Maza, Susana, additional, Walo-Delgado, Paulette E., additional, Maceski, Aleksandra, additional, Rodríguez-Martín, Eulalia, additional, Roldán, Ernesto, additional, Villarrubia, Noelia, additional, Saiz, Albert, additional, Blanco, Yolanda, additional, Sánchez, Pedro, additional, Carreón-Guarnizo, Ester, additional, Aladro, Yolanda, additional, Brieva, Luis, additional, Íñiguez, Cristina, additional, González-Suárez, Inés, additional, Rodríguez de Antonio, Luis A., additional, Masjuan, Jaime, additional, Costa-Frossard, Lucienne, additional, and Villar, Luisa M., additional

Published
2021
Full Text
View/download PDF

40. Does serum neurofilament light chain measurement influence therapeutic decisions in multiple sclerosis?

Author

Saposnik, Gustavo, Monreal, Enric, Medrano, Nicolas, García-Domínguez, Jose M, Querol, Luis, Meca-Lallana, Jose E, Landete, Lamberto, Salas, Elisa, Meca-Lallana, Virginia, García-Arcelay, Elena, Agüera-Morales, Eduardo, Martínez-Yélamos, Sergio, Gómez-Ballesteros, Rocío, Maurino, Jorge, Villar, Luisa M, and Caminero, Ana B

Abstract

• The capacity of serum neurofilament light chain (sNfL) measurement to accurately reflect ongoing neuro-axonal injury has sparked interest in its clinical utility across different neurological diseases. • Elevated sNfL levels in multiple sclerosis (MS) patients provide valuable insights into disease progression, predicting clinical outcomes, and assessing treatment response. • Challenges to its routine application include the clinical setting and certain behavioral factors of neurologists. • Efforts to provide targeted education on the benefits of sNfL testing are essential for facilitating its incorporation into personalized MS clinical decision-making. The assessment of serum neurofilament light chain (sNfL) concentration in multiple sclerosis (MS) is a useful tool for predicting clinical outcomes and assessing treatment response. However, its use in clinical practice is still limited. We aimed to assess how measurement of sNfL influences neurologists' treatment decisions in MS. We conducted a cross-sectional, web-based study in collaboration with the Spanish Society of Neurology. Neurologists involved in MS care were presented with different simulated case scenarios of patients experiencing either their first demyelinating MS event or a relapsing-remitting MS. The primary outcome was therapeutic inertia (TI), defined as the absence of treatment initiation or intensification despite elevated sNfL levels. Nine cases were included to estimate the TI score (range 0–9, where higher values represented a higher degree of TI). A total of 116 participants were studied. Mean age (standard deviation-SD) was 41.9 (10.1) years, 53.4 % male. Seventy-eight (67.2 %) were neurologists fully dedicated to the care of demyelinating disorders. Mean (SD) TI score was 3.65 (1.01). Overall, 92.2 % of participants (n = 107) presented TI in at least 2/9 case scenarios. The lack of full dedication to MS care (p = 0.014), preference for taking risks (p = 0.008), and low willingness to adopt evidence-based innovations (p = 0.009) were associated with higher TI scores in the multivariate analysis after adjustment for confounders. TI was a common phenomenon among neurologists managing MS patients when faced with the decision to initiate or escalate treatment based on elevated sNfL levels. Identifying factors associated with this phenomenon may help optimize treatment decisions in MS care. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

41. Brain region volumes and their relationship with disability progression and cognitive function in primary progressive multiple sclerosis

Author

Pérez‐Miralles, Francisco Carlos, primary, Prefasi, Daniel, additional, García‐Merino, Antonio, additional, Ara, José Ramón, additional, Izquierdo, Guillermo, additional, Meca‐Lallana, Virginia, additional, Gascón‐Giménez, Francisco, additional, Martínez‐Ginés, María Luisa, additional, Ramió‐Torrentà, Lluis, additional, Costa‐Frossard, Lucienne, additional, Fernández, Óscar, additional, Moreno‐García, Sara, additional, Maurino, Jorge, additional, Carreres‐Polo, Joan, additional, and Casanova, Bonaventura, additional

Published
2021
Full Text
View/download PDF

43. A Pilot Study to Explore Patient Satisfaction With a Virtual Rehabilitation Program in Multiple Sclerosis: The RehabVR Study Protocol

Author

Meca-Lallana, Virginia, primary, Prefasi, Daniel, additional, Alabarcez, Walter, additional, Hernández, Teresa, additional, García-Vaz, Fabiola, additional, Portaña, Angélica, additional, Gomis, David, additional, Téllez, Nieves, additional, García-Bernáldez, Cristina, additional, Mauriño, Jorge, additional, Medrano, Nicolás, additional, and Vázquez-Doce, Aránzazu, additional

Published
2020
Full Text
View/download PDF

45. Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: DISCOVER study

Author

Oreja-Guevara, Celia, Meca-Lallana, José E., Díaz-Díaz, Judit, Ara, José-Ramón, Hernández Pérez, Miguel Ángel, Gracia Gil, Julia, Alonso Torres, Ana María, Pilo de la Fuente, Belén, Ramió-Torrentà, Lluís, Eichau Madueño, Sara, Gascón-Giménez, Francisco, Casanova, Bonaventura, Martínez-Yélamos, Sergio, Aguado Valcárcel, Marta, Martínez Ginés, Maria Luisa, El Berdei Montero, Yasmina, López Real, Ana María, González-Quintanilla, Vicente, De Torres, Laura, Martínez-Rodríguez, José Enrique, Costa-Frossard, Lucienne, Garcés Redondo, Moisés, Labiano Fontcuberta, Andrés, Castellanos-Pinedo, Fernando, García Merino, Juan Antonio, Muñoz Fernández, Carmen, Castillo-Triviño, Tamara, Meca-Lallana, Virginia, Peña Martínez, Joaquín, Rodríguez-Antigüedad, Alfredo, Prieto González, José María, Agüera Morales, Eduardo, Pérez Molina, Inmaculada, Solar Sánchez, Dulce M, Herrera Varo, Nicolás, Romero Sevilla, Raúl, Gómez Vicente, Lidia, and Río, Jordi

Abstract

•SPMS represents a considerable negative impact on patients’ HRQoL•Unfortunately, there is a lack of data about the impact of SPMS disability on HRQoL•DISCOVER study is an observational, retrospective study in clinical practice in Spain•DISCOVER study assess the impact of SPMS on participants’ functional status and HRQoL•People with SPMS experience a high physical impact, fatigue and cognitive impairment

Published
2024
Full Text
View/download PDF

47. Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study

Author

Meca-Lallana, José, primary, Ayuso, Teresa, additional, Martínez-Yelamos, Sergio, additional, Durán, Carmen, additional, Contreras Martín, Yessica, additional, Herrera Navarro, Nicolás, additional, Pérez Sempere, Angel, additional, Álvarez-Cermeño, Jose C., additional, Millán Pascual, Jorge, additional, Meca-Lallana, Virginia, additional, Romero Sevilla, Raúl, additional, and Ricart, Javier, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results